The FDA has now resolved the shortages of Novo Nordisk and Eli Lilly’s blockbuster weight-loss drugs, which could spell the ...
This comes after the FDA said in October that Eli Lilly weight-loss treatments Mounjaro and Zepbound (which use the active ingredient tirzepatide, rather than semaglutide) were no longer on its list ...
Compounding pharmacies and other entities that have been allowed to make and distribute off-brand copies of the drugs during ...